The Food and Drug Administration on Monday approved Biogen’s new Alzheimer’s drug, a decision with far-reaching implications for patients, clinicians, and others. Here’s a rundown on some basic questions and answers about the drug, known as Aduhelm.
Who can get the drug?
The drug, tested in patients with mild cognitive impairment, is approved for patients with Alzheimer’s. They will need an MRI within one year of starting treatment and will also have to undergo more MRIs during treatment.